CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
EraNova Announces Positive Preliminary Economic Assessment for the Adanac Molybdenum Project: After-Tax NPV of $714.4 Million and 23.5% IRR
